News

PipelineReview.com1h
Pheast Therapeutics Announces First Patient Treated in Phase 1 Clinical Trial of PHST001 for Patients with Advanced Solid Tumors
REDWOOD CITY, CA, USA I April 14, 2025 I Pheast Therapeutics, a private biotechnology company developing novel therapies to unleash the power of macrophages ...
PipelineReview.com1h
Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating AU-007 in Combination With Nivolumab for Second-Line Treatment of Melanoma
LARKSPUR, CA, USA I April 14, 2025 I Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer care through development of ...
PipelineReview.com1h
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
INGELHEIM, Germany, and BOSTON, MA, USA I April 14, 2025 I Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research ...
PipelineReview.com1h
Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
PARIS, France I April 15, 2025 I Sanofi today shared new progress from its mid- to late-stage respiratory pipeline, including preliminary phase 2 results for ...
PipelineReview.com1h
Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
NEW YORK, NY, USA I April 14, 2025 I Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral ...
PipelineReview.com1h
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
PRINCETON, NJ, USA I April 14, 2025 I Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the ...
PipelineReview.com1d
European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy
BASEL, Switzerland I April 14, 2025 I Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Columvi® (glofitamab) in ...
PipelineReview.com5d
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
ISELIN, NJ, USA I April 08, 2025 I Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for ...
PipelineReview.com5d
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
SAINT HERBLAIN, France and SCHLIEREN, Zurich I April 9, 2025 I Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech ...
PipelineReview.com3d
Imdelltra® demonstrated superior overall survival in small cell lung cancer
First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy ...
PipelineReview.com5d
Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis
YANTAI, China I April 8, 2025 I On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and ...
PipelineReview.com5d
NexThera Completes First Patient Enrollment in U.S. Clinical Trial for ‘NT-101,’ an Eye Drop Treatment for Wet AMD
BUSAN, South Korea I April 09, 2025 I NexThera Co., Ltd. (CEO:SaeGwang Park) announced on April 9th that it has completed the first patient enrollment for its ...